Suzhou Highfine Biotech Co., Ltd. (SHE:301393)
China · Delayed Price · Currency is CNY 52.65
-0.35 (-0.66%)
At close: Feb 13, 2026
Suzhou Highfine Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 558.41 | 451.87 | 388.79 | 447.46 | 369.43 | 282.35 |
Other Revenue | - | - | - | - | 0.01 | - |
| 558.41 | 451.87 | 388.79 | 447.46 | 369.44 | 282.35 | |
Revenue Growth (YoY) | 35.11% | 16.22% | -13.11% | 21.12% | 30.85% | 47.63% |
Cost of Revenue | 347.23 | 272.51 | 243.44 | 254.68 | 197.97 | 150.36 |
Gross Profit | 211.19 | 179.36 | 145.36 | 192.78 | 171.47 | 131.99 |
Selling, General & Admin | 53.45 | 43.13 | 35.97 | 25.25 | 24.48 | 49.92 |
Research & Development | 40.38 | 35.99 | 28.47 | 22.26 | 14.8 | 22.46 |
Other Operating Expenses | 0.14 | -2.48 | 1.71 | 3.39 | 3.14 | 2.44 |
Operating Expenses | 86.98 | 76.64 | 66.15 | 50.9 | 44.03 | 74.65 |
Operating Income | 124.21 | 102.72 | 79.21 | 141.88 | 127.44 | 57.33 |
Interest Expense | -0.56 | -0.09 | -0.05 | -0.24 | -0.09 | -0.04 |
Interest & Investment Income | 36.9 | 40.68 | 29.01 | 1.07 | 1.96 | 2.04 |
Currency Exchange Gain (Loss) | 3.33 | 3.33 | -0.01 | 3.71 | -2.33 | -5.82 |
Other Non Operating Income (Expenses) | -2.1 | -0.77 | -0.18 | -0.16 | -0.13 | -0.11 |
EBT Excluding Unusual Items | 161.78 | 145.87 | 107.99 | 146.26 | 126.86 | 53.41 |
Gain (Loss) on Sale of Investments | 4.91 | 5.64 | 0.22 | - | 0 | - |
Gain (Loss) on Sale of Assets | -0.07 | -0.03 | -0 | -0.12 | -0.03 | 0 |
Asset Writedown | -12.23 | -0.36 | -0.08 | -0.28 | -0.08 | -0.1 |
Other Unusual Items | 3.52 | 3.52 | 4.36 | 3.11 | 2.3 | 1.31 |
Pretax Income | 157.92 | 154.64 | 112.49 | 148.96 | 129.05 | 54.62 |
Income Tax Expense | 20.96 | 20.58 | 13.51 | 19.59 | 17.65 | 14.22 |
Net Income | 136.96 | 134.05 | 98.97 | 129.37 | 111.4 | 40.4 |
Net Income to Common | 136.96 | 134.05 | 98.97 | 129.37 | 111.4 | 40.4 |
Net Income Growth | 17.65% | 35.44% | -23.50% | 16.13% | 175.73% | -30.49% |
Shares Outstanding (Basic) | 107 | 107 | 92 | 81 | 81 | 81 |
Shares Outstanding (Diluted) | 108 | 108 | 92 | 81 | 81 | 81 |
Shares Change (YoY) | -0.76% | 16.87% | 14.40% | 0.16% | -0.10% | 0.10% |
EPS (Basic) | 1.28 | 1.25 | 1.07 | 1.60 | 1.38 | 0.50 |
EPS (Diluted) | 1.27 | 1.24 | 1.07 | 1.60 | 1.38 | 0.50 |
EPS Growth | 18.55% | 15.89% | -33.13% | 15.94% | 176.00% | -30.56% |
Free Cash Flow | -91.32 | 18.62 | -32.64 | 57.27 | 22.42 | 21.74 |
Free Cash Flow Per Share | -0.85 | 0.17 | -0.35 | 0.71 | 0.28 | 0.27 |
Dividend Per Share | 0.400 | 0.390 | 0.250 | 0.250 | 2.500 | - |
Dividend Growth | 6.67% | 56.00% | - | -90.00% | - | - |
Gross Margin | 37.82% | 39.69% | 37.39% | 43.08% | 46.41% | 46.75% |
Operating Margin | 22.24% | 22.73% | 20.37% | 31.71% | 34.50% | 20.31% |
Profit Margin | 24.53% | 29.67% | 25.46% | 28.91% | 30.15% | 14.31% |
Free Cash Flow Margin | -16.35% | 4.12% | -8.40% | 12.80% | 6.07% | 7.70% |
EBITDA | 146.48 | 120.99 | 92.14 | 152.28 | 133.62 | 59.34 |
EBITDA Margin | 26.23% | 26.78% | 23.70% | 34.03% | 36.17% | 21.02% |
D&A For EBITDA | 22.27 | 18.27 | 12.94 | 10.41 | 6.18 | 2.01 |
EBIT | 124.21 | 102.72 | 79.21 | 141.88 | 127.44 | 57.33 |
EBIT Margin | 22.24% | 22.73% | 20.37% | 31.71% | 34.50% | 20.31% |
Effective Tax Rate | 13.27% | 13.31% | 12.01% | 13.15% | 13.68% | 26.03% |
Revenue as Reported | 558.41 | 451.87 | 388.79 | 447.46 | 369.44 | 282.35 |
Advertising Expenses | - | 2.36 | 2.03 | 0.47 | 0.64 | 0.4 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.